Are Peptides Safe? The FDA, the Evidence, and What to Watch For
Peptides are short chains of amino acids marketed widely for injury recovery, anti-aging, body composition, and sexual function. Most marketed peptides are not FDA-approved for those uses, and the FDA has explicitly flagged several, including BPC-157, CJC-1295, ipamorelin acetate, and AOD-9604, as substances that may present significant safety risks when compounded.
Most marketed peptides are not FDA-approved and lack controlled human safety data. The FDA has flagged several compounded peptides for potential immunogenicity, impurity, and characterisation risks. Side-effect profiles are poorly characterised, absence of reports is not evidence of safety.
Key Takeaways
- FDA approval is the exception, not the rule for marketed peptides. Most lack the controlled human trials required for approval.
- The FDA has identified BPC-157, CJC-1295, ipamorelin acetate, and AOD-9604 among compounded substances that may present significant safety risks.
- Common safety themes: immunogenicity, impurities, unvalidated dosing, infection risk from non-sterile injection, and unknown long-term effects.
- Peptides that affect the GH / IGF-1 axis (CJC-1295, ipamorelin, sermorelin, MK-677) can alter cardiovascular, metabolic, and fluid-balance responses.
- Disclose all peptide use to your clinicians, especially before surgery, pregnancy, cancer treatment, or immune-disease care.
- Check any peptide against your full medication list with the Allmeds drug interaction checker.
Which peptides are FDA-approved, and which are not?
| Peptide | FDA approval | Promoted uses |
|---|---|---|
| BPC-157 | Not approved | Injury recovery, gut healing, anti-inflammation |
| CJC-1295 | Not approved | Anti-aging, muscle gain, body composition |
| TB-500 | Not approved | Injury recovery, soft-tissue healing |
| Ipamorelin | Not approved | GH stimulation, anti-aging |
| AOD-9604 | Not approved | Weight loss (failed clinical trials) |
| Sermorelin | Limited approval | Diagnostic GH testing (historic); compounded for off-label use |
| PT-141 (bremelanotide) | Approved as Vyleesi | Premenopausal HSDD (approved); off-label use common |
| IGF-1 | Restricted | Mecasermin approved for severe primary IGF-1 deficiency; WADA-prohibited otherwise |
What are the main safety concerns with peptides?
The risks below are common across most peptide categories. They are amplified by gray-market sourcing, unsupervised use, and the absence of clinical trial data.
| Risk | What it means | Why it matters |
|---|---|---|
| Immunogenicity | Immune system reacts to the peptide or impurities, rash, hives, anaphylaxis | FDA-flagged for several peptides; reactions can be severe |
| Impurities | Compounded products may contain unlisted contaminants | Effects of contaminants are unpredictable and uncontrolled |
| Injection-site infection | Non-sterile technique can cause cellulitis, abscess, sepsis | Requires urgent medical care; gray-market kits often lack sterility guarantees |
| Unknown long-term effects | No multi-year human safety studies exist for most peptides | Risk profile beyond a few months is essentially unstudied |
| Drug interactions | Peptides may affect GH-axis, glucose, fluid balance, immune function | Implications for diabetes, anticoagulants, immunosuppressants, cancer therapy |
| Inconsistent potency | Compounded products vary in actual peptide content | Dose-response is unpredictable; underdosing or overdosing both possible |
Taking peptides alongside other medications?
Check any peptide against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
Peptide safety pages
Each page below covers the FDA position, known and unknown side effects, drug interactions, and what to disclose to your doctor, drawn from FDA, TGA, EMA, and peer-reviewed sources.
Common Questions About Peptide Safety
Most marketed peptides (BPC-157, CJC-1295, TB-500, ipamorelin acetate, AOD-9604, sermorelin, PT-141) are not FDA-approved for their promoted uses. A few, like sermorelin under specific prescription conditions, or PT-141 (Vyleesi) for low desire, have limited approved indications. The FDA has flagged several peptides for significant safety concerns when compounded.
Four recurring concerns: (1) limited or absent human clinical safety data; (2) potential immunogenicity, the immune system can react to peptides or impurities; (3) impurities and inconsistent potency in compounded or gray-market products; (4) infection and tissue damage from non-sterile injection practices.
No. Because most marketed peptides have not undergone the controlled human trials required for approval, side-effect profiles are not well characterised. The absence of reported side effects in marketing materials reflects a lack of adequate surveillance, not a proven safety profile.
Yes, but interactions are poorly studied for most peptides. Stimulating the growth hormone / IGF-1 axis can affect glucose regulation (diabetes medicines), fluid balance, and tissue growth (oncology and immunosuppressant interactions). Disclose any peptide use to your clinicians and pharmacist.
Yes, always. Clinicians need to know about all injected or compounded substances, particularly before surgery, pregnancy, cancer treatment, or any immune-disease care. Disclosure is essential for safe clinical decision-making.
References
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. fda.gov.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- World Anti-Doping Agency. WADA Prohibited List. wada-ama.org.
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53.
- U.S. Food & Drug Administration. FDA In Brief: FDA highlights concerns about compounding bulk drug substances. fda.gov.
Check any peptide against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.